ACT 📈 AlzChem - Overview
Exchange: XETRA • Country: Germany • Currency: EUR • Type: Common Stock • ISIN: DE000A2YNT30
ACT: Chemicals, Supplements, Pharmaceuticals, Coatings, Ceramics, Gases
AlzChem Group AG, together with its subsidiaries, develops, produces, and trades chemical products in Germany, European Union, rest of Europe, Asia, NAFTA region, and internationally. It operates through three segments: Specialty Chemicals, Basics & Intermediates, and Other & Holding. The company offers dietary supplements under the Creapure and Alipure brands; preparation of guanidinoacetic acid as a nutritional feed additives under the Creamino brand; creatine dietary supplements under the LIVADUR brand; products for pharmaceuticals under the Bioselect brand; curing agents, including accelerators for use in adhesives, powder coatings, printed circuit boards, and composites under the DYHARD name; and silicon nitride for ceramics, and electronics and solar applications under the SILZOT brand. It also provides fine and specialty chemicals, including products based on calcium carbide, calcium cyanamide, hydrogen cyanamide, dicyandiamide, guanidine, guanamines, and nitroguanidine, as well as aromatic and aliphatic nitriles; calcium cyanamide under the PERLKA name; germicide for use in pig pens under the ALZOGUR name; plant growth regulators under the Dormex and Sitofex name; and plant protection additives under the BREAK-THRU name. In addition, the company offers products for use in hot metal desulfurization and secondary metallurgy applications; and technical gases. Further, it provides chemical park operations and administrative services, as well as produces and distributes various infrastructure services. The company was founded in 1908 and is based in Trostberg, Germany. Web URL: https://www.alzchem.com
Additional Sources for ACT Stock
ACT Stock Overview
Market Cap in USD | 648m |
Sector | Basic Materials |
Industry | Specialty Chemicals |
GiC Sub-Industry | Specialty Chemicals |
IPO / Inception |
ACT Stock Ratings
Growth 5y | 80.9% |
Fundamental | 76.4% |
Dividend | 58.9% |
Rel. Strength Industry | 87249 |
Analysts | - |
Fair Price Momentum | 64.45 EUR |
Fair Price DCF | 279.85 EUR |
ACT Dividends
Dividend Yield 12m | 2.11% |
Yield on Cost 5y | 6.98% |
Annual Growth 5y | 3.13% |
Payout Consistency | 93.8% |
ACT Growth Ratios
Growth Correlation 3m | 69.8% |
Growth Correlation 12m | 90.8% |
Growth Correlation 5y | 55.8% |
CAGR 5y | 26.81% |
CAGR/Mean DD 5y | 2.05 |
Sharpe Ratio 12m | 2.07 |
Alpha | 109.09 |
Beta | 0.47 |
Volatility | 36.22% |
Current Volume | 12.2k |
Average Volume 20d | 13k |
What is the price of ACT stocks?
As of December 21, 2024, the stock is trading at EUR 57.00 with a total of 12,172 shares traded.
Over the past week, the price has changed by +0.69%, over one month by -3.00%, over three months by +40.58% and over the past year by +131.85%.
As of December 21, 2024, the stock is trading at EUR 57.00 with a total of 12,172 shares traded.
Over the past week, the price has changed by +0.69%, over one month by -3.00%, over three months by +40.58% and over the past year by +131.85%.
Is AlzChem a good stock to buy?
Yes, based on ValueRay Fundamental Analyses, AlzChem (XETRA:ACT) is currently (December 2024) a good stock to buy. It has a ValueRay Fundamental Rating of 76.39 and therefor a positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ACT as of December 2024 is 64.45. This means that ACT is currently undervalued and has a potential upside of +13.07% (Margin of Safety).
Yes, based on ValueRay Fundamental Analyses, AlzChem (XETRA:ACT) is currently (December 2024) a good stock to buy. It has a ValueRay Fundamental Rating of 76.39 and therefor a positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ACT as of December 2024 is 64.45. This means that ACT is currently undervalued and has a potential upside of +13.07% (Margin of Safety).
Is ACT a buy, sell or hold?
AlzChem has no consensus analysts rating.
AlzChem has no consensus analysts rating.
What are the forecast for ACT stock price target?
According to ValueRays Forecast Model, ACT AlzChem will be worth about 70.2 in December 2025. The stock is currently trading at 57.00. This means that the stock has a potential upside of +23.23%.
According to ValueRays Forecast Model, ACT AlzChem will be worth about 70.2 in December 2025. The stock is currently trading at 57.00. This means that the stock has a potential upside of +23.23%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 72.7 | 27.5% |
Analysts Target Price | - | - |
ValueRay Target Price | 70.2 | 23.2% |